Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise
Cue Biopharma surged Friday morning, the stock boosted by news of a fresh allergy drug license. The Boston biotech also unveiled a $30 million private placement and named Shao-Lee Lin as its new chief executive.